The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
Open accessAbstract
Bisphosphonates are used with increasing frequency in the management of skeletal complications in patients with breast cancer. In this paper, we have investigated whether bisphosphonates, besides their known beneficial effects on tumor-associated osteoclastic resorption, are capable of inhibiting breast cancer cell adhesion to bone matrix. For that we used two in vitro models for bone matrix (cortical bone slices and cryostat sections of trabecular bone from neonatal mouse tails). Four bone matrix-bound nitrogen-containing bisphosphonates (pamidronate, olpadronate, alendronate, and ibandronate) inhibited adhesion and spreading of breast cancer cells to bone dose-dependently, whereas etidronate and clodronate had little or no effect. Strikingly, the relative order of potency of the bisphosphonates in inhibiting the adhesion of cancer cells to cortical and trabecular bone corresponded to their relative antiresorptive potencies in vivo as well as their ranking in in vitro bone resorption assays with predictive value for their clinical efficacy. It appears that nitrogen-containing bisphosphonates alter selectively the adhesive properties of the extracellular bone matrix preventing the attachment of breast cancer cells to it. Besides the beneficial effects of bisphosphonates on tumor-induced osteoclastic resorption, the previously unrecognized effect presented in this paper makes these agents suitable for earlier pharmacologic intervention in patients with breast cancer at risk of developing bone metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of Bone Biology: By Bilezikian, Raisz and Rodan. Academic Press, London, U.K., 1996
Compston, J. E. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2431019.x · Cited by 1,370
The clinical course of bone metastases from breast cancer
Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084
(1990) · Elsevier eBooks · doi:10.1016/c2009-0-34738-8 · Cited by 1,069
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Ross, F. P., Chappel, J., Alvarez, J. I., Sander, D., Butler, W. T., Farach-Carson, M. C., Mintz, K. A., Robey, P. G., Teitelbaum, S. L., & Cheresh, D. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98430-9 · Cited by 537
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Resorption of bone by isolated rabbit osteoclasts
Chambers, T. J., Revell, P. A., Fuller, K., & Athanasou, N. A. (1984) · Journal of Cell Science · doi:10.1242/jcs.66.1.383 · Cited by 413
Davies, J., Warwick, J., Totty, N., Philp, R., Helfrich, M., & Horton, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.109.4.1817 · Cited by 365
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Schenk, R., Eggli, P., Fleisch, H., & Rosini, S. (1986) · Calcified Tissue International · doi:10.1007/bf02555748 · Cited by 315
Mechanisms of bone destruction in the development of skeletal metastases
GALASKO, C. S. B. (1976) · Nature · doi:10.1038/263507a0 · Cited by 272
Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy
Sato, M., & Grasser, W. (1990) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650050107 · Cited by 264
Osteolytic bone metastasis in breast cancer
Yoneda, T., Sasaki, A., & Mundy, G. R. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666208 · Cited by 246
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239
Direct resorption of bone by human breast cancer cells in vitro
EILON, G., & MUNDY, G. R. (1978) · Nature · doi:10.1038/276726a0 · Cited by 235
Helfrich, M. H., Nesbitt, S. A., Dorey, E. L., & Horton, M. A. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070314 · Cited by 214
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92755-1 · Cited by 209
van Holten-Verzantvoort, A. T., Bijvoet, O. L. M., Hermans, J., Harinck, H. I. J., Elte, J. W. F., Beex, L. V. A. M., Cleton, F. J., Kroon, H. M., Vermey, P., Neijt, J. P., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92555-4 · Cited by 202
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
van Holten-Verzantvoort, A. T., Kroon, H. M., Bijvoet, O. L., Cleton, F. J., Beex, L. V., Blijham, G., Hermans, J., Neijt, J. P., Papapoulos, S. E., & Sleeboom, H. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.491 · Cited by 196
Self-citationDr. Löwik, C. W. G. M., Van Der Pluijm, G., Van Der Wee-Pals, L. J. A., Van Treslong-De Groot, H. B., & Bijvoet, O. L. M. (1988) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650030210 · Cited by 191
Self-citationRelationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins
GALASKO, C. S. B., & BENNETT, A. (1976) · Nature · doi:10.1038/263508a0 · Cited by 183
Antiresorptive dose-response relationships across three generations of bisphosphonates.
Sietsema, W. K., Ebetino, F. H., Salvagno, A. M., & Bevan, J. A. (1989) · PubMed · Cited by 139
Mechanisms of osteolytic bone destruction
Mundy, G. R. (1991) · Bone · doi:10.1016/8756-3282(91)90057-p · Cited by 131
Boonekamp, P. M., Löwik, C. W. G. M., van der Wee-Pals, L. J. A., Ml, V. W.-V. L., & Bijvoet, O. L. (1987) · PubMed · Cited by 100
Self-citationvan Holten-Verzantvoort, A. T. M., Zwinderman, A. H., Aaronson, N. K., Hermans, J., van Emmerik, B., van Dam, F. S. A. M., van den Bos, B., Bijvoet, O. L. M., & Cleton, F. J. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90212-v · Cited by 92
Ueber die im Organismus künstlich erzeugbaren Verkalkungen
Kóssa, G. (1901) · Hungarian Veterinary Archive · Cited by 80
Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone.
van der Pluijm, G., Vloedgraven, H. J., Ivanov, B., Robey, F. A., Grzesik, W. J., Robey, P. G., Papapoulos, S. E., & Löwik, C. W. G. M. (1996) · PubMed · Cited by 67
Self-citationPapapoulos, S. E., Hoekman, K., Löwik, C. W. G. M., Vermeij, P., & Bijvoet, O. L. M. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040518 · Cited by 67
Self-citationOsteolytic bone metastases in breast carcinoma pathogenesis, morbidity and biphosphonate treatment
Elte, J. W. F., Bijvoet, O. L. M., Cleton, F. J., van Oosterom, A. T., & Sleeboom, H. P. (1986) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(86)90117-3 · Cited by 65
Bone metastases in breast cancer, prostate cancer and myeloma.
Paterson, A. H. (1987) · PubMed · Cited by 64
van der Pluijm, G., Mouthaan, H., Baas, C., de Groot, H., Papapoulos, S. E., & Löwik, C. W. G. M. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090709 · Cited by 42
Self-citationMechanisms involved in the metastasis of cancer to bone
Orr, F. W., Kostenuik, P. J., Sanchez-Sweatman, O. H., & Singh, G. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00662140 · Cited by 41
Kostenuik, P. J., Singh, G., Suyama, K. L., & Orr, F. W. (1992) · Clinical & Experimental Metastasis · doi:10.1007/bf00133470 · Cited by 34
Development of skeletal metastases.
Kitazawa, S., & Maeda, S. (1995) · PubMed · Cited by 28
van der Pluijm, G., Binderup, L., Bramm, E., van der Wee-Pals, L. J. A., de Groot, H., Binderup, E., Löwik, C. W. G. M., & Papapoulos, S. E. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070815 · Cited by 24
Self-citationResorption of bone by isolated rabbit osteoclasts
Chambers, T. J., Revell, P. A., Fuller, K., & Athanasou, N. A. (1984) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(84)90057-2 · Cited by 19
Mechanisms of Osteolytic Bone Destruction
Mundy, G. R., Boyce, B. F., & Yoneda, T. (1994) · Springer eBooks · doi:10.1007/978-3-642-78596-2_7 · Cited by 7
Colucci, S. C., Minielf, V., Zambonin, G., & Grano, M. (1995) · Bone · doi:10.1016/8756-3282(96)87947-6 · Cited by 3
Physiology of Bone and Metabolic Approaches to the Treatment of Skeletal Metastases
Kanis, J. А., Gray, R. E., Urwin, G. H., Murray, S., & Hamdy, N. A. T. (1987) · Springer eBooks · doi:10.1007/978-1-4613-2049-4_35 · Cited by 1
Cited by
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Metadata
- Authors
- van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S.
- Venue
- Journal of Clinical Investigation
- Published
- 1996-08-01
- Volume
- 98
- Issue
- 3
- Pages
- 698-705
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2007001439
- Cited by
- 305
- References
- 42
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.